Tevogen Bio to host panel on AI’s role in Biopharma innovation

Anika Therapeutics, Inc., a leading global joint preservation company specializing in early intervention orthopedics, has announced a key participation at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, set to take place in San Francisco. Dr. Cheryl Blanchard, President and CEO of Anika, will deliver a presentation at the event on Thursday, January 16, 2025, at 9:45 AM PT / 12:45 PM ET.

This high-profile conference is renowned for gathering industry leaders, innovators, and investors in the healthcare and life sciences sectors, offering a platform for companies to showcase their strategies, achievements, and future growth plans. Dr. Blanchard’s presentation will provide insights into Anika's innovative approaches to joint preservation and early orthopedic interventions, as well as its strategic priorities and recent advancements.

In addition to the presentation, Anika's management team will actively participate in one-on-one investor meetings throughout the event, creating an opportunity for deeper engagement with institutional investors, analysts, and industry stakeholders. These meetings are pivotal in fostering investor confidence and highlighting the company's value proposition in the evolving medtech landscape.

The presentation will be streamed live via webcast on the Events and Webcasts page within the Investors section of Anika Therapeutics’ website. For those unable to attend the live session, a recording will be archived and accessible on the company’s website for 30 days following the event, ensuring broader accessibility to stakeholders.